Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Legal Brief Claims Pharma Companies Misled Medical Journal

By Drug Discovery Trends Editor | March 2, 2016

Details surrounding the approval of cardiovascular drug rivaroxaban (Xarelto) are questionable, but new events revealed Tuesday have further muddied the waters.

Last month, an investigation published by the British Medical Journal, questioned the results of data in the ROCKET-AF trial, which served as the backbone for rivaroxaban’s approval. A major concern is that the portable device used to monitor and calibrate medication usage in the trial may have been seriously defective.

Now, in a report published first by The New York Times, lawyers for patients suing Johnson & Johnson and Bayer over the safety of rivaroxaban claim that a letter published in The New England Journal of Medicine omitted “critical laboratory data.”

The companies may have been “complicit by staying silent, helping deceive the editors while the companies were in the midst of providing the very same data to regulators in the U.S. and Europe,” reported The New York Times.

Duke University’s Clinical Research Institute, who did the study on behalf of Bayer, published a letter in February in the New England Journal of Medicine stating that it had re-analyzed the trial’s results and stands by its conclusions. Problems with the device “did not have any significant clinical effect on the primary efficacy and safety outcomes in the trial,” the researchers wrote.

The re-analysis findings “are in line with the sensitivity analyses conducted by Bayer and Janssen Pharmaceuticals (part of Johnson & Johnson), which also affirm the results of the ROCKET-AF study and the positive benefit-risk profile of rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation,” said Janssen in a statement to Drug Discovery & Development, in February.

Read more: BMJ Investigation Casts Doubt on Validity of Rivaroxaban Trial

Duke University and Johnson & Johnson contend they worked independently. Top editors at The New England Journal of Medicine told The New York Times they did not know that separate laboratory data existed until a reporter contacted them last week, “but they dismissed its relevance and said they stood by the article’s analysis.”

The ROCKET-AF trial compared the number of strokes and bleeding events experienced by patients taking rivaroxaban with those taking the older anticoagulant drug warfarin. A concern is that faulty results (potentially caused by a defective device) may have led doctors to give patients the incorrect dose of warfarin, which could have favored rivaroxaban.

Rivaroxaban (Xarelto) is a blockbuster drug for stroke prevention in atrial fibrillation that gained approval from both U.S. and European regulators. The drug had nearly $2 billion in U.S. sales last year.

Bayer and Johnson & Johnson hired Duke University’s Clinical Research Institute to run a three-year clinical trial involving more than 14,000 patients, which led to rivaroxaban’s approval. The trial’s results have come under scrutiny since September, when the companies notified regulators that a device used in the trial — the Alere INRatio and INRatio2 PT/INR Monitor System — had malfunctioned.

Read the New York Times article here.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE